Targeting the complex interactions between microbiota, host epithelial and immune cells in inflammatory bowel disease

Pharmacological Research

Volumn 113, Issue , 2016, Pages 574-584

  Hirata, Yoshihiro ^a   Ihara, Sozaburo ^a   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Dysbiosis; Genetic susceptibility; Inflammatory bowel disease; Knockout mouse; Microbiota; Therapy

Indexed keywords

CYTOKINE;

DRUG TARGETING; ENVIRONMENTAL FACTOR; EPITHELIUM CELL; EXPERIMENTAL COLITIS; EXPERIMENTAL MODEL; FUTUROLOGY; GENETIC SUSCEPTIBILITY; HOST PATHOGEN INTERACTION; HOST SUSCEPTIBILITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; LEUKOCYTE FUNCTION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG EFFECTS; ETIOLOGY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INTESTINE MUCOSA; MICROBIOLOGY; MICROFLORA;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MICROBIOTA;

EID: 84989824430     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.09.044     Document Type: Review

References (135)

1. [1] Garrett, W.S., Gordon, J.I., Glimcher, L.H., Homeostasis and inflammation in the intestine. Cell 140:6 (2010), 859–870.
2. [2] Donaldson, G.P., Lee, S.M., Mazmanian, S.K., Gut biogeography of the bacterial microbiota. Nat. Rev. Microbiol. 14:1 (2016), 20–32.
3. [3] Peterson, L.W., Artis, D., Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 14:3 (2014), 141–153.
4. [4] Huttenhower, C., Kostic, A.D., Xavier, R.J., Inflammatory bowel disease as a model for translating the microbiome. Immunity 40:6 (2014), 843–854.
5. [5] Molodecky, N.A., Soon, I.S., Rabi, D.M., Ghali, W.A., Ferris, M., Chernoff, G., Benchimol, E.I., Panaccione, R., Ghosh, S., Barkema, H.W., Kaplan, G.G., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142:1 (2012), 46–54 e42; quiz e30.
6. [6] Sun, L., Nava, G.M., Stappenbeck, T.S., Host genetic susceptibility, dysbiosis, and viral triggers in inflammatory bowel disease. Curr. Opin. Gastroenterol. 27:4 (2011), 321–327.
7. [7] de Souza, H.S., Fiocchi, C., Immunopathogenesis of IBD: current state of the art. Nat. Rev. Gastroenterol. Hepatol. 13:1 (2016), 13–27.
8. [8] Ek, W.E., D'Amato, M., Halfvarson, J., The history of genetics in inflammatory bowel disease. Ann. Gastroenterol. 27:4 (2014), 294–303.
9. [9] Van Limbergen, J., Radford-Smith, G., Satsangi, J., Advances in IBD genetics. Nat. Rev. Gastroenterol. Hepatol. 11:6 (2014), 372–385.
10. [10] Hugot, J.P., Laurent-Puig, P., Gower-Rousseau, C., Olson, J.M., Lee, J.C., Beaugerie, L., Naom, I., Dupas, J.L., Van Gossum, A., Orholm, M., Bonaiti-Pellie, C., Weissenbach, J., Mathew, C.G., Lennard-Jones, J.E., Cortot, A., Colombel, J.F., Thomas, G., Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 379:6568 (1996), 821–823.
11. [11] Hugot, J.P., Chamaillard, M., Zouali, H., Lesage, S., Cezard, J.P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C.A., Gassull, M., Binder, V., Finkel, Y., Cortot, A., Modigliani, R., Laurent-Puig, P., Gower-Rousseau, C., Macry, J., Colombel, J.F., Sahbatou, M., Thomas, G., Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411:6837 (2001), 599–603.
12. [12] Ogura, Y., Bonen, D.K., Inohara, N., Nicolae, D.L., Chen, F.F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R.H., Achkar, J.P., Brant, S.R., Bayless, T.M., Kirschner, B.S., Hanauer, S.B., Nunez, G., Cho, J.H., A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411:6837 (2001), 603–606.
13. [13] Duerr, R.H., Taylor, K.D., Brant, S.R., Rioux, J.D., Silverberg, M.S., Daly, M.J., Steinhart, A.H., Abraham, C., Regueiro, M., Griffiths, A., Dassopoulos, T., Bitton, A., Yang, H., Targan, S., Datta, L.W., Kistner, E.O., Schumm, L.P., Lee, A.T., Gregersen, P.K., Barmada, M.M., Rotter, J.I., Nicolae, D.L., Cho, J.H., A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314:5804 (2006), 1461–1463.
14. [14] Hampe, J., Franke, A., Rosenstiel, P., Till, A., Teuber, M., Huse, K., Albrecht, M., Mayr, G., De La Vega, F.M., Briggs, J., Gunther, S., Prescott, N.J., Onnie, C.M., Hasler, R., Sipos, B., Folsch, U.R., Lengauer, T., Platzer, M., Mathew, C.G., Krawczak, M., Schreiber, S., A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 39:2 (2007), 207–211.
15. [15] Jostins, L., Ripke, S., Weersma, R.K., Duerr, R.H., McGovern, D.P., Hui, K.Y., Lee, J.C., Schumm, L.P., Sharma, Y., Anderson, C.A., Essers, J., Mitrovic, M., Ning, K., Cleynen, I., Theatre, E., Spain, S.L., Raychaudhuri, S., Goyette, P., Wei, Z., Abraham, C., Achkar, J.P., Ahmad, T., Amininejad, L., Ananthakrishnan, A.N., Andersen, V., Andrews, J.M., Baidoo, L., Balschun, T., Bampton, P.A., Bitton, A., Boucher, G., Brand, S., Buning, C., Cohain, A., Cichon, S., D'Amato, M., De Jong, D., Devaney, K.L., Dubinsky, M., Edwards, C., Ellinghaus, D., Ferguson, L.R., Franchimont, D., Fransen, K., Gearry, R., Georges, M., Gieger, C., Glas, J., Haritunians, T., Hart, A., Hawkey, C., Hedl, M., Hu, X., Karlsen, T.H., Kupcinskas, L., Kugathasan, S., Latiano, A., Laukens, D., Lawrance, I.C., Lees, C.W., Louis, E., Mahy, G., Mansfield, J., Morgan, A.R., Mowat, C., Newman, W., Palmieri, O., Ponsioen, C.Y., Potocnik, U., Prescott, N.J., Regueiro, M., Rotter, J.I., Russell, R.K., Sanderson, J.D., Sans, M., Satsangi, J., Schreiber, S., Simms, L.A., Sventoraityte, J., Targan, S.R., Taylor, K.D., Tremelling, M., Verspaget, H.W., De Vos, M., Wijmenga, C., Wilson, D.C., Winkelmann, J., Xavier, R.J., Zeissig, S., Zhang, B., Zhang, C.K., Zhao, H., Silverberg, M.S., Annese, V., Hakonarson, H., Brant, S.R., Radford-Smith, G., Mathew, C.G., Rioux, J.D., Schadt, E.E., Daly, M.J., Franke, A., Parkes, M., Vermeire, S., Barrett, J.C., Cho, J.H., Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491:7422 (2012), 119–124.
16. [16] Yamazaki, K., McGovern, D., Ragoussis, J., Paolucci, M., Butler, H., Jewell, D., Cardon, L., Takazoe, M., Tanaka, T., Ichimori, T., Saito, S., Sekine, A., Iida, A., Takahashi, A., Tsunoda, T., Lathrop, M., Nakamura, Y., Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum. Mol. Genet. 14:22 (2005), 3499–3506.
17. [17] Franke, A., McGovern, D.P., Barrett, J.C., Wang, K., Radford-Smith, G.L., Ahmad, T., Lees, C.W., Balschun, T., Lee, J., Roberts, R., Anderson, C.A., Bis, J.C., Bumpstead, S., Ellinghaus, D., Festen, E.M., Georges, M., Green, T., Haritunians, T., Jostins, L., Latiano, A., Mathew, C.G., Montgomery, G.W., Prescott, N.J., Raychaudhuri, S., Rotter, J.I., Schumm, P., Sharma, Y., Simms, L.A., Taylor, K.D., Whiteman, D., Wijmenga, C., Baldassano, R.N., Barclay, M., Bayless, T.M., Brand, S., Buning, C., Cohen, A., Colombel, J.F., Cottone, M., Stronati, L., Denson, T., De Vos, M., D'Inca, R., Dubinsky, M., Edwards, C., Florin, T., Franchimont, D., Gearry, R., Glas, J., Van Gossum, A., Guthery, S.L., Halfvarson, J., Verspaget, H.W., Hugot, J.P., Karban, A., Laukens, D., Lawrance, I., Lemann, M., Levine, A., Libioulle, C., Louis, E., Mowat, C., Newman, W., Panes, J., Phillips, A., Proctor, D.D., Regueiro, M., Russell, R., Rutgeerts, P., Sanderson, J., Sans, M., Seibold, F., Steinhart, A.H., Stokkers, P.C., Torkvist, L., Kullak-Ublick, G., Wilson, D., Walters, T., Targan, S.R., Brant, S.R., Rioux, J.D., D'Amato, M., Weersma, R.K., Kugathasan, S., Griffiths, A.M., Mansfield, J.C., Vermeire, S., Duerr, R.H., Silverberg, M.S., Satsangi, J., Schreiber, S., Cho, J.H., Annese, V., Hakonarson, H., Daly, M.J., Parkes, M., Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 42:12 (2010), 1118–1125.
18. [18] Tommasini, A., Pirrone, A., Palla, G., Taddio, A., Martelossi, S., Crovella, S., Ventura, A., The universe of immune deficiencies in Crohn's disease: a new viewpoint for an old disease?. Scand. J. Gastroenterol. 45:10 (2010), 1141–1149.
19. [19] Rioux, J.D., Xavier, R.J., Taylor, K.D., Silverberg, M.S., Goyette, P., Huett, A., Green, T., Kuballa, P., Barmada, M.M., Datta, L.W., Shugart, Y.Y., Griffiths, A.M., Targan, S.R., Ippoliti, A.F., Bernard, E.J., Mei, L., Nicolae, D.L., Regueiro, M., Schumm, L.P., Steinhart, A.H., Rotter, J.I., Duerr, R.H., Cho, J.H., Daly, M.J., Brant, S.R., Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat. Genet. 39:5 (2007), 596–604.
20. [20] Saitoh, T., Fujita, N., Jang, M.H., Uematsu, S., Yang, B.G., Satoh, T., Omori, H., Noda, T., Yamamoto, N., Komatsu, M., Tanaka, K., Kawai, T., Tsujimura, T., Takeuchi, O., Yoshimori, T., Akira, S., Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 456:7219 (2008), 264–268.
21. [21] Cadwell, K., Patel, K.K., Maloney, N.S., Liu, T.C., Ng, A.C., Storer, C.E., Head, R.D., Xavier, R., Stappenbeck, T.S., Virgin, H.W., Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell 141:7 (2010), 1135–1145.
22. [22] Marchiando, A.M., Ramanan, D., Ding, Y., Gomez, L.E., Hubbard-Lucey, V.M., Maurer, K., Wang, C., Ziel, J.W., van Rooijen, N., Nunez, G., Finlay, B.B., Mysorekar, I.U., Cadwell, K., A deficiency in the autophagy gene Atg16L1 enhances resistance to enteric bacterial infection. Cell Host Microbe 14:2 (2013), 216–224.
23. [23] Parkes, M., Barrett, J.C., Prescott, N.J., Tremelling, M., Anderson, C.A., Fisher, S.A., Roberts, R.G., Nimmo, E.R., Cummings, F.R., Soars, D., Drummond, H., Lees, C.W., Khawaja, S.A., Bagnall, R., Burke, D.A., Todhunter, C.E., Ahmad, T., Onnie, C.M., McArdle, W., Strachan, D., Bethel, G., Bryan, C., Lewis, C.M., Deloukas, P., Forbes, A., Sanderson, J., Jewell, D.P., Satsangi, J., Mansfield, J.C., Cardon, L., Mathew, C.G., Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat. Genet. 39:7 (2007), 830–832.
24. [24] Orvedahl, A., Sumpter, R. Jr., Xiao, G., Ng, A., Zou, Z., Tang, Y., Narimatsu, M., Gilpin, C., Sun, Q., Roth, M., Forst, C.V., Wrana, J.L., Zhang, Y.E., Luby-Phelps, K., Xavier, R.J., Xie, Y., Levine, B., Image-based genome-wide siRNA screen identifies selective autophagy factors. Nature 480:7375 (2011), 113–117.
25. [25] Yang, S.K., Hong, M., Zhao, W., Jung, Y., Baek, J., Tayebi, N., Kim, K.M., Ye, B.D., Kim, K.J., Park, S.H., Lee, I., Lee, E.J., Kim, W.H., Cheon, J.H., Kim, Y.H., Jang, B.I., Kim, H.S., Choi, J.H., Koo, J.S., Lee, J.H., Jung, S.A., Lee, Y.J., Jang, J.Y., Shin, H.D., Kang, D., Youn, H.S., Liu, J., Song, K., Genome-wide association study of Crohn's disease in Koreans revealed three new susceptibility loci and common attributes of genetic susceptibility across ethnic populations. Gut 63:1 (2014), 80–87.
26. [26] VanDussen, K.L., Liu, T.C., Li, D., Towfic, F., Modiano, N., Winter, R., Haritunians, T., Taylor, K.D., Dhall, D., Targan, S.R., Xavier, R.J., McGovern, D.P., Stappenbeck, T.S., Genetic variants synthesize to produce paneth cell phenotypes that define subtypes of Crohn's disease. Gastroenterology 146:1 (2014), 200–209.
27. [27] Adolph, T.E., Tomczak, M.F., Niederreiter, L., Ko, H.J., Bock, J., Martinez-Naves, E., Glickman, J.N., Tschurtschenthaler, M., Hartwig, J., Hosomi, S., Flak, M.B., Cusick, J.L., Kohno, K., Iwawaki, T., Billmann-Born, S., Raine, T., Bharti, R., Lucius, R., Kweon, M.N., Marciniak, S.J., Choi, A., Hagen, S.J., Schreiber, S., Rosenstiel, P., Kaser, A., Blumberg, R.S., Paneth cells as a site of origin for intestinal inflammation. Nature 503:7475 (2013), 272–276.
28. [28] Steinbach, E.C., Plevy, S.E., The role of macrophages and dendritic cells in the initiation of inflammation in IBD. Inflamm. Bowel Dis. 20:1 (2014), 166–175.
29. [29] Bernstein, C.N., Shanahan, F., Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut 57:9 (2008), 1185–1191.
30. [30] Manichanh, C., Borruel, N., Casellas, F., Guarner, F., The gut microbiota in IBD. Nat. Rev. Gastroenterol. Hepatol. 9:10 (2012), 599–608.
31. [31] Rook, G.A., Hygiene hypothesis and autoimmune diseases. Clin. Rev. Allergy Immunol. 42:1 (2012), 5–15.
32. [32] Cholapranee, A., Ananthakrishnan, A.N., Environmental hygiene and risk of inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm. Bowel Dis. 22:9 (2016), 2191–2199.
33. [33] Garcia Rodriguez, L.A., Ruigomez, A., Panes, J., Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology 130:6 (2006), 1588–1594.
34. [34] Chiodini, R.J., Van Kruiningen, H.J., Thayer, W.R., Merkal, R.S., Coutu, J.A., Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohn's disease. Dig. Dis. Sci. 29:12 (1984), 1073–1079.
35. [35] Liverani, E., Scaioli, E., Cardamone, C., Dal Monte, P., Belluzzi, A., Mycobacterium avium subspecies paratuberculosis in the etiology of Crohn's disease, cause or epiphenomenon?. World J. Gastroenterol. 20:36 (2014), 13060–13070.
36. [36] Feller, M., Huwiler, K., Stephan, R., Altpeter, E., Shang, A., Furrer, H., Pfyffer, G.E., Jemmi, T., Baumgartner, A., Egger, M., Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infect. Dis. 7:9 (2007), 607–613.
37. [37] Rolhion, N., Darfeuille-Michaud, A., Adherent-invasive Escherichia coli in inflammatory bowel disease. Inflamm. Bowel Dis. 13:10 (2007), 1277–1283.
38. [38] Darfeuille-Michaud, A., Neut, C., Barnich, N., Lederman, E., Di Martino, P., Desreumaux, P., Gambiez, L., Joly, B., Cortot, A., Colombel, J.F., Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 115:6 (1998), 1405–1413.
39. [39] Boudeau, J., Glasser, A.L., Masseret, E., Joly, B., Darfeuille-Michaud, A., Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease. Infect. Immun. 67:9 (1999), 4499–4509.
40. [40] Darfeuille-Michaud, A., Boudeau, J., Bulois, P., Neut, C., Glasser, A.L., Barnich, N., Bringer, M.A., Swidsinski, A., Beaugerie, L., Colombel, J.F., High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127:2 (2004), 412–421.
41. [41] Martin, H.M., Campbell, B.J., Hart, C.A., Mpofu, C., Nayar, M., Singh, R., Englyst, H., Williams, H.F., Rhodes, J.M., Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 127:1 (2004), 80–93.
42. [42] Mei, L., Targan, S.R., Landers, C.J., Dutridge, D., Ippoliti, A., Vasiliauskas, E.A., Papadakis, K.A., Fleshner, P.R., Rotter, J.I., Yang, H., Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology 130:4 (2006), 1078–1085.
43. [43] Arnott, I.D., Landers, C.J., Nimmo, E.J., Drummond, H.E., Smith, B.K., Targan, S.R., Satsangi, J., Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am. J. Gastroenterol. 99:12 (2004), 2376–2384.
44. [44] Mow, W.S., Vasiliauskas, E.A., Lin, Y.C., Fleshner, P.R., Papadakis, K.A., Taylor, K.D., Landers, C.J., Abreu-Martin, M.T., Rotter, J.I., Yang, H., Targan, S.R., Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 126:2 (2004), 414–424.
45. [45] Rolhion, N., Carvalho, F.A., Darfeuille-Michaud, A., OmpC and the sigma(E) regulatory pathway are involved in adhesion and invasion of the Crohn's disease-associated Escherichia coli strain LF82. Mol. Microbiol. 63:6 (2007), 1684–1700.
46. [46] Giaffer, M.H., Holdsworth, C.D., Duerden, B.I., Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut 33:5 (1992), 646–650.
47. [47] Petersen, C., Round, J.L., Defining dysbiosis and its influence on host immunity and disease. Cell. Microbiol. 16:7 (2014), 1024–1033.
48. [48] Lepage, P., Hasler, R., Spehlmann, M.E., Rehman, A., Zvirbliene, A., Begun, A., Ott, S., Kupcinskas, L., Dore, J., Raedler, A., Schreiber, S., Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 141:1 (2011), 227–236.
49. [49] Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L., Nalin, R., Jarrin, C., Chardon, P., Marteau, P., Roca, J., Dore, J., Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55:2 (2006), 205–211.
50. [50] Gevers, D., Kugathasan, S., Denson, L.A., Vazquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S.J., Yassour, M., Morgan, X.C., Kostic, A.D., Luo, C., Gonzalez, A., McDonald, D., Haberman, Y., Walters, T., Baker, S., Rosh, J., Stephens, M., Heyman, M., Markowitz, J., Baldassano, R., Griffiths, A., Sylvester, F., Mack, D., Kim, S., Crandall, W., Hyams, J., Huttenhower, C., Knight, R., Xavier, R.J., The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 15:3 (2014), 382–392.
51. [51] Waidmann, M., Bechtold, O., Frick, J.S., Lehr, H.A., Schubert, S., Dobrindt, U., Loeffler, J., Bohn, E., Autenrieth, I.B., Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice. Gastroenterology 125:1 (2003), 162–177.
52. [52] Rath, H.C., Herfarth, H.H., Ikeda, J.S., Grenther, W.B., Hamm, T.E. Jr., Balish, E., Taurog, J.D., Hammer, R.E., Wilson, K.H., Sartor, R.B., Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J. Clin. Invest. 98:4 (1996), 945–953.
53. [53] Bloom, S.M., Bijanki, V.N., Nava, G.M., Sun, L., Malvin, N.P., Donermeyer, D.L., Dunne, W.M. Jr., Allen, P.M., Stappenbeck, T.S., Commensal Bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. Cell Host Microbe 9:5 (2011), 390–403.
54. [54] Elinav, E., Strowig, T., Kau, A.L., Henao-Mejia, J., Thaiss, C.A., Booth, C.J., Peaper, D.R., Bertin, J., Eisenbarth, S.C., Gordon, J.I., Flavell, R.A., NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145:5 (2011), 745–757.
55. [55] Monteleone, G., Kumberova, A., Croft, N.M., McKenzie, C., Steer, H.W., MacDonald, T.T., Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J. Clin. Invest. 108:4 (2001), 601–609.
56. [56] Ramalingam, R., Larmonier, C.B., Thurston, R.D., Midura-Kiela, M.T., Zheng, S.G., Ghishan, F.K., Kiela, P.R., Dendritic cell-specific disruption of TGF-beta receptor II leads to altered regulatory T cell phenotype and spontaneous multiorgan autoimmunity. J. Immunol. 189:8 (2012), 3878–3893.
57. [57] Ihara, S., Hirata, Y., Serizawa, T., Suzuki, N., Sakitani, K., Kinoshita, H., Hayakawa, Y., Nakagawa, H., Ijichi, H., Tateishi, K., Koike, K., TGF-beta signaling in dendritic cells governs colonic homeostasis by controlling epithelial differentiation and the luminal microbiota. J. Immunol. 196:11 (2016), 4603–4613.
58. [58] Brenner, D., Blaser, H., Mak, T.W., Regulation of tumour necrosis factor signalling: live or let die. Nat. Rev. Immunol. 15:6 (2015), 362–374.
59. [59] Amiot, A., Peyrin-Biroulet, L., Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Ther. Adv. Gastroenterol. 8:2 (2015), 66–82.
60. [60] Monteleone, G., Biancone, L., Marasco, R., Morrone, G., Marasco, O., Luzza, F., Pallone, F., Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112:4 (1997), 1169–1178.
61. [61] Peluso, I., Pallone, F., Monteleone, G., Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World J. Gastroenterol. 12:35 (2006), 5606–5610.
62. [62] Neurath, M.F., IL-23: a master regulator in Crohn disease. Nat. Med. 13:1 (2007), 26–28.
63. [63] Uhlig, H.H., McKenzie, B.S., Hue, S., Thompson, C., Joyce-Shaikh, B., Stepankova, R., Robinson, N., Buonocore, S., Tlaskalova-Hogenova, H., Cua, D.J., Powrie, F., Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25:2 (2006), 309–318.
64. [64] Neurath, M.F., Fuss, I., Kelsall, B.L., Stuber, E., Strober, W., Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182:5 (1995), 1281–1290.
65. [65] Becker, C., Dornhoff, H., Neufert, C., Fantini, M.C., Wirtz, S., Huebner, S., Nikolaev, A., Lehr, H.A., Murphy, A.J., Valenzuela, D.M., Yancopoulos, G.D., Galle, P.R., Karow, M., Neurath, M.F., Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J. Immunol. 177:5 (2006), 2760–2764.
66. [66] Elson, C.O., Cong, Y., Weaver, C.T., Schoeb, T.R., McClanahan, T.K., Fick, R.B., Kastelein, R.A., Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 132:7 (2007), 2359–2370.
67. [67] Sandborn, W.J., Feagan, B.G., Fedorak, R.N., Scherl, E., Fleisher, M.R., Katz, S., Johanns, J., Blank, M., Rutgeerts, P., A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135:4 (2008), 1130–1141.
68. [68] Sandborn, W.J., Gasink, C., Gao, L.L., Blank, M.A., Johanns, J., Guzzo, C., Sands, B.E., Hanauer, S.B., Targan, S., Rutgeerts, P., Ghosh, S., de Villiers, W.J., Panaccione, R., Greenberg, G., Schreiber, S., Lichtiger, S., Feagan, B.G., Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 367:16 (2012), 1519–1528.
69. [69] Lobaton, T., Vermeire, S., Van Assche, G., Rutgeerts, P., Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment. Pharmacol. Ther. 39:6 (2014), 579–594.
70. [70] Danese, S., Panes, J., Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology 147:5 (2014), 981–989.
71. [71] Ghosh, S., Goldin, E., Gordon, F.H., Malchow, H.A., Rask-Madsen, J., Rutgeerts, P., Vyhnalek, P., Zadorova, Z., Palmer, T., Donoghue, S., Natalizumab for active Crohn's disease. N. Engl. J. Med. 348:1 (2003), 24–32.
72. [72] Sandborn, W.J., Colombel, J.F., Enns, R., Feagan, B.G., Hanauer, S.B., Lawrance, I.C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S., van Deventer, S., Goldblum, R., Despain, D., Hogge, G.S., Rutgeerts, P., Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353:18 (2005), 1912–1925.
73. [73] Targan, S.R., Feagan, B.G., Fedorak, R.N., Lashner, B.A., Panaccione, R., Present, D.H., Spehlmann, M.E., Rutgeerts, P.J., Tulassay, Z., Volfova, M., Wolf, D.C., Hernandez, C., Bornstein, J., Sandborn, W.J., Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132:5 (2007), 1672–1683.
74. [74] Feagan, B.G., Rutgeerts, P., Sands, B.E., Hanauer, S., Colombel, J.F., Sandborn, W.J., Van Assche, G., Axler, J., Kim, H.J., Danese, S., Fox, I., Milch, C., Sankoh, S., Wyant, T., Xu, J., Parikh, A., Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369:8 (2013), 699–710.
75. [75] Sandborn, W.J., Feagan, B.G., Rutgeerts, P., Hanauer, S., Colombel, J.F., Sands, B.E., Lukas, M., Fedorak, R.N., Lee, S., Bressler, B., Fox, I., Rosario, M., Sankoh, S., Xu, J., Stephens, K., Milch, C., Parikh, A., Vedolizumab as induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 369:8 (2013), 711–721.
76. [76] Dabritz, J., Granulocyte macrophage colony-stimulating factor and the intestinal innate immune cell homeostasis in Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol. 306:6 (2014), G455–65.
77. [77] Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., Steinman, R.M., Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:6 (1992), 1693–1702.
78. [78] Hirata, Y., Egea, L., Dann, S.M., Eckmann, L., Kagnoff, M.F., GM-CSF-facilitated dendritic cell recruitment and survival govern the intestinal mucosal response to a mouse enteric bacterial pathogen. Cell Host Microbe 7:2 (2010), 151–163.
79. [79] Dieckgraefe, B.K., Korzenik, J.R., Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 360:9344 (2002), 1478–1480.
80. [80] Korzenik, J.R., Dieckgraefe, B.K., Valentine, J.F., Hausman, D.F., Gilbert, M.J., Sargramostim for active Crohn's disease. N. Engl. J. Med. 352:21 (2005), 2193–2201.
81. [81] Zorzi, F., Angelucci, E., Sedda, S., Pallone, F., Monteleone, G., Smad7 antisense oligonucleotide-based therapy for inflammatory bowel diseases. Dig. Liver Dis. 45:7 (2013), 552–555.
82. [82] Monteleone, G., Neurath, M.F., Ardizzone, S., Di Sabatino, A., Fantini, M.C., Castiglione, F., Scribano, M.L., Armuzzi, A., Caprioli, F., Sturniolo, G.C., Rogai, F., Vecchi, M., Atreya, R., Bossa, F., Onali, S., Fichera, M., Corazza, G.R., Biancone, L., Savarino, V., Pica, R., Orlando, A., Pallone, F., Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N. Engl. J. Med. 372:12 (2015), 1104–1113.
83. [83] Babyatsky, M.W., Rossiter, G., Podolsky, D.K., Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 110:4 (1996), 975–984.
84. [84] Contini, P., Negrini, S., Bodini, G., Trucchi, C., Ubezio, G., Strada, P., Savarino, V., Ghio, M., Granulocytes and monocytes apheresis induces upregulation of TGFβ1 in patients with active ulcerative colitis: a possible involvement of soluble HLA-I. J. Clin. Apher., 2016, 10.1002/jca.21466.
85. [85] Ihara, S., Yamaji, Y., Kinoshita, H., Yamada, A., Hirata, Y., Hasegawa, K., Sugawara, Y., Kokudo, N., Koike, K., First case report of de novo ulcerative colitis developing after orthotopic liver transplantation successfully treated by granulocyte and monocyte apheresis. Transplant. Proc. 46:7 (2014), 2414–2417.
86. [86] Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., Lees, C., Ho, G.T., Satsangi, J., Bloom, S., On behalf of the IBD Section of the British Society of Gastroenterology, Guidelines for the management of inflammatory bowel disease in adults. Gut 60:5 (2011), 571–607.
87. [87] Nakao, A., Afrakhte, M., Moren, A., Nakayama, T., Christian, J.L., Heuchel, R., Itoh, S., Kawabata, M., Heldin, N.E., Heldin, C.H., ten Dijke, P., Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389:6651 (1997), 631–635.
88. [88] Monteleone, G., Fantini, M.C., Onali, S., Zorzi, F., Sancesario, G., Bernardini, S., Calabrese, E., Viti, F., Monteleone, I., Biancone, L., Pallone, F., Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol. Ther. 20:4 (2012), 870–876.
89. [89] Gorelik, L., Flavell, R.A., Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12:2 (2000), 171–181.
90. [90] Tanoue, T., Atarashi, K., Honda, K., Development and maintenance of intestinal regulatory T cells. Nat. Rev. Immunol. 16:5 (2016), 295–309.
91. [91] Khan, K.J., Ullman, T.A., Ford, A.C., Abreu, M.T., Abadir, A., Marshall, J.K., Talley, N.J., Moayyedi, P., Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am. J. Gastroenterol. 106:4 (2011), 661–673.
92. [92] Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., Cheng, G., Yamasaki, S., Saito, T., Ohba, Y., Taniguchi, T., Takeda, K., Hori, S., Ivanov, I.I., Umesaki, Y., Itoh, K., Honda, K., Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331:6015 (2011), 337–341.
93. [93] Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., Kim, S., Fritz, J.V., Wilmes, P., Ueha, S., Matsushima, K., Ohno, H., Olle, B., Sakaguchi, S., Taniguchi, T., Morita, H., Hattori, M., Honda, K., Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500:7461 (2013), 232–236.
94. [94] Furusawa, Y., Obata, Y., Fukuda, S., Endo, T.A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., Takahashi, M., Fukuda, N.N., Murakami, S., Miyauchi, E., Hino, S., Atarashi, K., Onawa, S., Fujimura, Y., Lockett, T., Clarke, J.M., Topping, D.L., Tomita, M., Hori, S., Ohara, O., Morita, T., Koseki, H., Kikuchi, J., Honda, K., Hase, K., Ohno, H., Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504:7480 (2013), 446–450.
95. [95] Hayashi, A., Sato, T., Kamada, N., Mikami, Y., Matsuoka, K., Hisamatsu, T., Hibi, T., Roers, A., Yagita, H., Ohteki, T., Yoshimura, A., Kanai, T., A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. Cell Host Microbe 13:6 (2013), 711–722.
96. [96] Kashiwagi, I., Morita, R., Schichita, T., Komai, K., Saeki, K., Matsumoto, M., Takeda, K., Nomura, M., Hayashi, A., Kanai, T., Yoshimura, A., Smad2 and smad3 inversely regulate TGF-beta autoinduction in Clostridium butyricum-activated dendritic cells. Immunity 43:1 (2015), 65–79.
97. [97] Colman, R.J., Rubin, D.T., Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J. Crohns Colitis 8:12 (2014), 1569–1581.
98. [98] Moayyedi, P., Surette, M.G., Kim, P.T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J.K., Kassam, Z., Reinisch, W., Lee, C.H., Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology, 149(1), 2015 102-109 e6.
99. [99] Rossen, N.G., Fuentes, S., van der Spek, M.J., Tijssen, J.G., Hartman, J.H., Duflou, A., Lowenberg, M., van den Brink, G.R., Mathus-Vliegen, E.M., de Vos, W.M., Zoetendal, E.G., D'Haens, G.R., Ponsioen, C.Y., Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology, 149(1), 2015 (110-118 e4).
100. [100] Grinspan, A.M., Kelly, C.R., Fecal microbiota transplantation for ulcerative colitis: not just yet. Gastroenterology 149:1 (2015), 15–18.
101. [101] Hansson, G.C., Role of mucus layers in gut infection and inflammation. Curr. Opin. Microbiol. 15:1 (2012), 57–62.
102. [102] Sartor, R.B., Gut microbiota: optimal sampling of the intestinal microbiota for research. Nat. Rev. Gastroenterol. Hepatol. 12:5 (2015), 253–254.
103. [103] Johansson, M.E., Sjovall, H., Hansson, G.C., The gastrointestinal mucus system in health and disease. Nat. Rev. Gastroenterol. Hepatol. 10:6 (2013), 352–361.
104. [104] Gaudier, E., Jarry, A., Blottiere, H.M., de Coppet, P., Buisine, M.P., Aubert, J.P., Laboisse, C., Cherbut, C., Hoebler, C., Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. Am. J. Physiol. Gastrointest. Liver Physiol. 287:6 (2004), G1168–G1174.
105. [105] Burger-van Paassen, N., Vincent, A., Puiman, P.J., van der Sluis, M., Bouma, J., Boehm, G., van Goudoever, J.B., van Seuningen, I., Renes, I.B., The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. Biochem. J 420:2 (2009), 211–219.
106. [106] Vernia, P., Annese, V., Bresci, G., d'Albasio, G., D'Inca, R., Giaccari, S., Ingrosso, M., Mansi, C., Riegler, G., Valpiani, D., Caprilli, R., Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur. J. Clin. Invest. 33:3 (2003), 244–248.
107. [107] Jakobsson, H.E., Rodriguez-Pineiro, A.M., Schutte, A., Ermund, A., Boysen, P., Bemark, M., Sommer, F., Backhed, F., Hansson, G.C., Johansson, M.E., The composition of the gut microbiota shapes the colon mucus barrier. EMBO Rep. 16:2 (2015), 164–177.
108. [108] Henderson, P., van Limbergen, J.E., Schwarze, J., Wilson, D.C., Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease. Inflamm. Bowel Dis. 17:1 (2011), 382–395.
109. [109] Michielan, A., D'Inca, R., Intestinal permeability in inflammatory bowel disease: pathogenesis clinical evaluation, and therapy of leaky gut. Mediators Inflamm., 2015, 2015, 628157.
110. [110] Suenaert, P., Bulteel, V., Lemmens, L., Noman, M., Geypens, B., Van Assche, G., Geboes, K., Ceuppens, J.L., Rutgeerts, P., Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am. J. Gastroenterol. 97:8 (2002), 2000–2004.
111. [111] Zakostelska, Z., Kverka, M., Klimesova, K., Rossmann, P., Mrazek, J., Kopecny, J., Hornova, M., Srutkova, D., Hudcovic, T., Ridl, J., Tlaskalova-Hogenova, H., Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS One, 6(11), 2011, e27961.
112. [112] Patel, R.M., Myers, L.S., Kurundkar, A.R., Maheshwari, A., Nusrat, A., Lin, P.W., Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function. Am. J. Pathol. 180:2 (2012), 626–635.
113. [113] Cario, E., Barrier-protective function of intestinal epithelial Toll-like receptor 2. Mucosal Immunol. 1:Suppl. 1 (2008), S62–S66.
114. [114] Cario, E., Gerken, G., Podolsky, D.K., Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 132:4 (2007), 1359–1374.
115. [115] Nishimura, M., Kuboi, Y., Muramoto, K., Kawano, T., Imai, T., Chemokines as novel therapeutic targets for inflammatory bowel disease. Ann. N. Y. Acad. Sci. 1173 (2009), 350–356.
116. [116] Papadakis, K.A., Prehn, J., Moreno, S.T., Cheng, L., Kouroumalis, E.A., Deem, R., Breaverman, T., Ponath, P.D., Andrew, D.P., Green, P.H., Hodge, M.R., Binder, S.W., Targan, S.R., CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 121:2 (2001), 246–254.
117. [117] Rivera-Nieves, J., Ho, J., Bamias, G., Ivashkina, N., Ley, K., Oppermann, M., Cominelli, F., Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology 131:5 (2006), 1518–1529.
118. [118] Keshav, S., Vanasek, T., Niv, Y., Petryka, R., Howaldt, S., Bafutto, M., Racz, I., Hetzel, D., Nielsen, O.H., Vermeire, S., Reinisch, W., Karlen, P., Schreiber, S., Schall, T.J., Bekker, P., A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLoS One, 8(3), 2013, e60094.
119. [119] Rimoldi, M., Chieppa, M., Salucci, V., Avogadri, F., Sonzogni, A., Sampietro, G.M., Nespoli, A., Viale, G., Allavena, P., Rescigno, M., Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat. Immunol. 6:5 (2005), 507–514.
120. [120] Kim, S.C., Tonkonogy, S.L., Albright, C.A., Tsang, J., Balish, E.J., Braun, J., Huycke, M.M., Sartor, R.B., Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology 128:4 (2005), 891–906.
121. [121] Lupp, C., Robertson, M.L., Wickham, M.E., Sekirov, I., Champion, O.L., Gaynor, E.C., Finlay, B.B., Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2:2 (2007), 119–129.
122. [122] Nones, K., Knoch, B., Dommels, Y.E., Paturi, G., Butts, C., McNabb, W.C., Roy, N.C., Multidrug resistance gene deficient (mdr1a-/-) mice have an altered caecal microbiota that precedes the onset of intestinal inflammation. J. Appl. Microbiol. 107:2 (2009), 557–566.
123. [123] Garrett, W.S., Gallini, C.A., Yatsunenko, T., Michaud, M., DuBois, A., Delaney, M.L., Punit, S., Karlsson, M., Bry, L., Glickman, J.N., Gordon, J.I., Onderdonk, A.B., Glimcher, L.H., Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe 8:3 (2010), 292–300.
124. [124] Powell, N., Walker, A.W., Stolarczyk, E., Canavan, J.B., Gokmen, M.R., Marks, E., Jackson, I., Hashim, A., Curtis, M.A., Jenner, R.G., Howard, J.K., Parkhill, J., MacDonald, T.T., Lord, G.M., The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cells. Immunity 37:4 (2012), 674–684.
125. [125] Hashimoto, T., Perlot, T., Rehman, A., Trichereau, J., Ishiguro, H., Paolino, M., Sigl, V., Hanada, T., Hanada, R., Lipinski, S., Wild, B., Camargo, S.M., Singer, D., Richter, A., Kuba, K., Fukamizu, A., Schreiber, S., Clevers, H., Verrey, F., Rosenstiel, P., Penninger, J.M., ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 487:7408 (2012), 477–481.
126. [126] Carvalho, F.A., Koren, O., Goodrich, J.K., Johansson, M.E., Nalbantoglu, I., Aitken, J.D., Su, Y., Chassaing, B., Walters, W.A., Gonzalez, A., Clemente, J.C., Cullender, T.C., Barnich, N., Darfeuille-Michaud, A., Vijay-Kumar, M., Knight, R., Ley, R.E., Gewirtz, A.T., Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. Cell Host Microbe 12:2 (2012), 139–152.
127. [127] Devkota, S., Wang, Y., Musch, M.W., Leone, V., Fehlner-Peach, H., Nadimpalli, A., Antonopoulos, D.A., Jabri, B., Chang, E.B., Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature 487:7405 (2012), 104–108.
128. [128] Couturier-Maillard, A., Secher, T., Rehman, A., Normand, S., De Arcangelis, A., Haesler, R., Huot, L., Grandjean, T., Bressenot, A., Delanoye-Crespin, A., Gaillot, O., Schreiber, S., Lemoine, Y., Ryffel, B., Hot, D., Nunez, G., Chen, G., Rosenstiel, P., Chamaillard, M., NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J. Clin. Invest. 123:2 (2013), 700–711.
129. [129] Larmonier, C.B., Laubitz, D., Hill, F.M., Shehab, K.W., Lipinski, L., Midura-Kiela, M.T., McFadden, R.M., Ramalingam, R., Hassan, K.A., Golebiewski, M., Besselsen, D.G., Ghishan, F.K., Kiela, P.R., Reduced colonic microbial diversity is associated with colitis in NHE3-deficient mice. Am. J. Physiol. Gastrointest. Liver Physiol. 305:10 (2013), G667–77.
130. [130] Vereecke, L., Vieira-Silva, S., Billiet, T., van Es, J.H., Mc Guire, C., Slowicka, K., Sze, M., van den Born, M., De Hertogh, G., Clevers, H., Raes, J., Rutgeerts, P., Vermeire, S., Beyaert, R., van Loo, G., A20 controls intestinal homeostasis through cell-specific activities. Nat. Commun., 5, 2014, 5103.
131. [131] Alkadhi, S., Kunde, D., Cheluvappa, R., Randall-Demllo, S., Eri, R., The murine appendiceal microbiome is altered in spontaneous colitis and its pathological progression. Gut Pathog., 6, 2014, 25.
132. [132] Martinez-Medina, M., Denizot, J., Dreux, N., Robin, F., Billard, E., Bonnet, R., Darfeuille-Michaud, A., Barnich, N., Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut 63:1 (2014), 116–124.
133. [133] Morampudi, V., Dalwadi, U., Bhinder, G., Sham, H.P., Gill, S.K., Chan, J., Bergstrom, K.S., Huang, T., Ma, C., Jacobson, K., Gibson, D.L., Vallance, B.A., The goblet cell-derived mediator RELM-beta drives spontaneous colitis in Muc2-deficient mice by promoting commensal microbial dysbiosis. Mucosal Immunol. 9:5 (2016), 1218–1233.
134. [134] Kamdar, K., Khakpour, S., Chen, J., Leone, V., Brulc, J., Mangatu, T., Antonopoulos, D.A., Chang, E.B., Kahn, S.A., Kirschner, B.S., Young, G., DePaolo, R.W., Genetic and metabolic signals during acute enteric bacterial infection alter the microbiota and drive progression to chronic inflammatory disease. Cell Host Microbe 19:1 (2016), 21–31.
135. [135] Coulombe, G., Langlois, A., De Palma, G., Langlois, M.J., McCarville, J.L., Gagne-Sanfacon, J., Perreault, N., Feng, G.S., Bercik, P., Boudreau, F., Verdu, E.F., Rivard, N., SHP-2 phosphatase prevents colonic inflammation by controlling secretory cell differentiation and maintaining host-microbiota homeostasis. J. Cell. Physiol. 231:11 (2016), 2529–2540.